List of Excipients in Branded Drug BASIC CARE LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

Generic Drugs Containing BASIC CARE LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

Company	Ingredient	NDC	Excipient
L Perrigo Company	loperamide hydrochloride, simethicone	0113-7119	ACESULFAME POTASSIUM
L Perrigo Company	loperamide hydrochloride, simethicone	0113-7119	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
L Perrigo Company	loperamide hydrochloride, simethicone	0113-7119	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in BASIC CARE LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE?

# Of NDCs	Excipient
2	ACESULFAME POTASSIUM
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
2	CELLULOSE, MICROCRYSTALLINE

# Basic Care Loperamide Hydrochloride and Simethicone: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 6, 2026

Basic Care Loperamide Hydrochloride and Simethicone is an over-the-counter combination product for diarrhea, gas, bloating, and cramping. Its active ingredients are loperamide hydrochloride, an intestinal antimotility agent, and simethicone, an antiflatulent. The commercial proposition is a low-cost alternative to branded products such as Imodium A-D Multi-Symptom Relief.

The product’s primary competitive advantages are regulatory simplicity, established active ingredients, low manufacturing cost, and broad consumer recognition. Its principal constraints are limited differentiation, OTC labeling restrictions, safety concerns associated with loperamide misuse, and the absence of a meaningful composition-of-matter patent position. Commercial value is concentrated in formulation execution, retailer access, packaging, dosage-form improvements, and supply-chain economics.

What is Basic Care Loperamide Hydrochloride and Simethicone?

Basic Care Loperamide Hydrochloride and Simethicone is an oral solid dosage form containing:

Component	Function
Loperamide hydrochloride	Reduces intestinal motility and stool frequency
Simethicone	Reduces symptoms caused by excess gas
Pharmaceutical excipients	Support tablet compression, disintegration, coating, stability, and manufacturability

Typical U.S. products in this category contain 2 mg of loperamide hydrochloride and 125 mg of simethicone per caplet. The product is positioned for adults and children aged 12 years and older, subject to the applicable Drug Facts labeling and dosing limits.[1]

Loperamide is regulated as an OTC antidiarrheal active ingredient under the FDA’s OTC monograph framework. Simethicone is regulated as an OTC antiflatulent active ingredient.[2,3] The combination addresses two symptoms in one product, which supports a price premium over single-ingredient loperamide.

The product is generally sold as caplets or tablets rather than as a liquid. This reduces packaging cost, improves transport stability, and simplifies retail distribution.

What excipients are used in loperamide and simethicone caplets?

The commercial excipient system must accommodate two active ingredients with different physical properties. Loperamide hydrochloride is used at a low dose, while simethicone is used at a substantially higher dose and may create blend-uniformity and compression challenges.

Common excipient categories include:

Excipient category	Commercial purpose	Relevance to this product
Microcrystalline cellulose	Diluent and compression aid	Provides tablet bulk and mechanical strength
Dibasic calcium phosphate or similar mineral filler	Diluent and structural support	Supports robust caplet compression
Croscarmellose sodium or sodium starch glycolate	Superdisintegrant	Promotes tablet breakup after ingestion
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and reduces manufacturing variability
Magnesium stearate	Lubricant	Reduces sticking and die-wall friction
Povidone	Binder	Improves granule and tablet integrity
Talc	Glidant, anti-adherent, or coating aid	May support processing and surface performance
Film-coating polymers	Appearance, swallowability, and protection	Can improve consumer acceptance and handling

The exact inactive-ingredient list is product-specific and must be controlled through the approved label and manufacturing documentation. The main technical issue is not the number of excipients but the interaction between simethicone, powder flow, tablet hardness, disintegration, and dose uniformity.

How does simethicone affect excipient selection?

Simethicone is a hydrophobic silicone-based material. In a solid oral product, it can impair wetting and slow disintegration if it is poorly distributed or over-lubricated. The formulation must maintain adequate dispersion without causing tablet friability, sticking, or excessive compression force.

A practical formulation strategy is to use:

1. A high-functionality diluent system with predictable compaction.
2. A superdisintegrant at a level sufficient to offset hydrophobicity.
3. Controlled lubricant addition, particularly magnesium stearate.
4. A glidant to improve flow and content uniformity.
5. Particle-size and blending controls for simethicone-containing granules or premixes.

Excessive lubricant exposure can reduce tablet wetting and delay disintegration. This is especially relevant when the product relies on direct compression.

How does low-dose loperamide affect content uniformity?

Loperamide hydrochloride represents a small fraction of total tablet mass. That creates a blend-uniformity risk despite the product’s relatively simple composition. Commercial controls should address:

• Loperamide particle-size distribution.
• Premixing or geometric dilution.
• Blend segregation during transfer and compression.
• Sampling plans for low-dose uniformity.
• In-process weight and assay controls.
• Hold-time stability of the final blend.

A formulation with stronger flow and segregation resistance can reduce batch failures and improve manufacturing yield. Those savings may be more commercially important than small differences in excipient cost.

What formulation patents protect loperamide and simethicone products?

The active ingredients have no meaningful new chemical entity patent opportunity for a conventional OTC combination. Loperamide has been marketed for decades, and simethicone is an established antiflatulent. A standard 2 mg/125 mg caplet is unlikely to receive meaningful exclusivity from the active ingredients alone.

Potential intellectual-property protection can arise from:

• A novel modified-release profile.
• A distinct orally disintegrating or chewable dosage form.
• Taste-masking technology.
• A specific simethicone dispersion or granulation process.
• A moisture-barrier coating.
• A fixed-dose combination with an unusual release or delivery profile.
• A manufacturing process that produces a defined particle-size or dissolution profile.
• Packaging that improves stability or child resistance.

These rights would be formulation, manufacturing, or packaging patents rather than composition-of-matter patents. Their commercial value depends on whether an alternative manufacturer can design around the claims.

What is the Orange Book status of Basic Care loperamide and simethicone?

A conventional OTC product marketed under the FDA monograph pathway generally does not rely on an Orange Book-listed new-drug patent estate. The Orange Book is primarily relevant to approved prescription and certain approved nonprescription drug applications with listed patents and exclusivity.[4]

For this product category, the relevant regulatory framework is:

Issue	Assessment
OTC monograph pathway	Core regulatory route
New drug application	Not generally required for a compliant monograph product
Orange Book patent listing	No expected strategic role for a standard monograph product
Paragraph IV challenge	Generally not applicable without an NDA-listed patent
Biosimilar exposure	None
Generic substitution	Product competes in the OTC private-label market
Market exclusivity	Primarily brand, retailer, formulation, and distribution-based

The absence of an Orange Book patent does not eliminate commercial barriers. Manufacturing qualification, supplier approvals, quality systems, retailer contracts, and packaging compliance can still delay a competing launch.

When does loperamide and simethicone lose exclusivity?

The active ingredients have no meaningful remaining market exclusivity in the conventional sense. The product competes in an open OTC market where entry is controlled by regulatory compliance and commercial execution rather than by a near-term patent cliff.

Key dates are best understood as regulatory and commercial milestones rather than patent expirations:

Milestone	Strategic significance
Loperamide OTC monograph availability	Allows compliant manufacturers to market the active ingredient without relying on an innovator patent
Simethicone OTC monograph availability	Supports broad antiflatulent competition
Brand launch of combination products	Creates consumer and retailer familiarity but not durable exclusivity
Private-label launch	Converts established demand into retailer-controlled volume
Product reformulation	May create a new quality, stability, or intellectual-property position

There is no conventional “loss of exclusivity” date comparable to a protected prescription medicine. The relevant risk is competitive erosion from other store brands, national brands, online retailers, and contract manufacturers.

What regulatory status applies to Basic Care loperamide and simethicone?

The product falls within a mature OTC category. Loperamide and simethicone are recognized OTC actives for their respective indications under FDA regulations and monograph requirements.[2,3]

The label must control:

• Indications.
• Age restrictions.
• Dose per administration.
• Maximum daily dose.
• Duration of self-treatment.
• Warnings for fever, bloody stool, mucus, and worsening symptoms.
• Warnings against use in certain pediatric populations.
• Warnings concerning excessive loperamide use.
• Directions for discontinuation and medical consultation.

The product’s regulatory risk is concentrated in labeling, manufacturing quality, adverse-event monitoring, and compliance with current FDA requirements for OTC products. It does not have the clinical-development burden associated with a new prescription combination.

What safety issues affect commercial positioning?

Loperamide has a well-established safety profile at labeled doses. However, misuse at excessive doses has been associated with serious cardiac events, including QT prolongation, torsades de pointes, cardiac arrest, and death. FDA has addressed misuse risk through safety communications and packaging-related measures.[5]

This creates a commercial tradeoff:

• Larger package counts may improve revenue per transaction.
• Smaller package counts may reduce misuse exposure and lower retail compliance risk.
• Clear warning language may protect the brand but reduce impulse purchasing.
• Unit-dose or blister packaging may improve dose control and tamper visibility.

Retailers may favor pack sizes and packaging formats that reduce diversion and support responsible use.

How strong is the patent estate for Basic Care loperamide and simethicone?

The patent estate is weak for a standard caplet but potentially stronger for differentiated delivery and manufacturing technology.

IP category	Strength for standard product	Commercial assessment
Loperamide composition patent	Very low	Mature active ingredient
Simethicone composition patent	Very low	Long-established excipient-active antiflatulent
Fixed-dose combination patent	Low	Broad claims likely difficult to sustain
Tablet formulation patent	Low to moderate	Depends on narrow technical limitations
Taste-masking patent	Moderate	More relevant to chewables and pediatric products
Orally disintegrating formulation	Moderate	Potential differentiation if performance is demonstrated
Manufacturing-process patent	Moderate	Can protect yield, uniformity, or stability improvements
Packaging patent	Low to moderate	Useful for child resistance, unit dosing, or moisture protection
Trademark and trade dress	Commercially relevant	Important for private-label shelf and online recognition

The strongest defensible position would combine regulatory compliance, validated manufacturing performance, retailer exclusivity, and a differentiated dosage form. A broad patent claim covering “loperamide plus simethicone” would face substantial validity and prior-art risks.

What commercial opportunities exist for excipient innovation?

Excipient innovation can create value even without strong patent exclusivity. The best opportunities address consumer convenience, manufacturing reliability, or channel-specific requirements.

Orally disintegrating tablets

An orally disintegrating tablet could target consumers who have difficulty swallowing during acute gastrointestinal illness. The formulation would need rapid disintegration without excessive friability, poor taste, or simethicone separation.

Potential excipient tools include:

• Mannitol for mouthfeel and rapid dissolution.
• Crospovidone or croscarmellose sodium for disintegration.
• Flavor systems and sweeteners for taste control.
• Silicon dioxide for flow.
• Low-moisture processing to protect stability.

Taste masking is important because loperamide can create an unpleasant sensory profile. A successful product could command a higher price than a standard caplet, although it would face greater packaging and manufacturing complexity.

Chewable tablets

Chewables could offer convenience for travel and consumers who prefer not to swallow caplets. The main barriers are taste, grittiness, dose uniformity, and simethicone dispersion.

A chewable platform may support:

• Fruit or mint flavor systems.
• Polyols for texture and sweetness.
• Reduced tablet hardness.
• Controlled particle size for a smoother mouthfeel.
• Moisture-resistant blister packaging.

Chewable products also carry a greater risk of accidental pediatric consumption, making child-resistant packaging and prominent labeling important.

Fast-dispersing travel formats

Travel packs, unit-dose blisters, and pocket-sized sachets could expand the product beyond traditional medicine-cabinet use. The commercial opportunity is strongest in convenience retail, e-commerce, airports, hospitality, and travel health.

Packaging rather than excipient technology may provide the primary differentiation. Unit-dose packaging can also reduce dose errors and improve inventory control.

Lower-cost private-label formulations

The largest near-term opportunity is likely a cost-optimized caplet that maintains acceptable disintegration, stability, and appearance while reducing manufacturing complexity.

Cost levers include:

• Direct compression instead of wet granulation.
• Fewer excipients.
• Common, dual-function excipients.
• Standardized tooling.
• High-speed blister or bottle packaging.
• Dual sourcing for loperamide and simethicone.
• Reduced coating weight.
• Larger production campaigns.

The risk is that an aggressive cost reduction can produce slower disintegration, poor tablet hardness, or unacceptable appearance. A low-cost product that generates complaints can lose retailer support.

How does Basic Care compare with branded loperamide and simethicone products?

Factor	Basic Care	Imodium A-D Multi-Symptom Relief	Generic pharmacy brands
Brand owner	Retailer or private-label sponsor	Kenvue	Various manufacturers and retailers
Active ingredients	Loperamide hydrochloride and simethicone	Same combination in comparable products	Often the same
Patent advantage	Limited	Limited for mature actives
Consumer trust	Retailer-dependent	Strong national-brand recognition	Variable
Price	Usually lower	Usually higher	Low to moderate
Retailer leverage	High for the sponsoring retailer	Lower than private label	Depends on channel
Differentiation	Packaging, price, availability	Brand, advertising, recognition	Price and pharmacy access
Manufacturing barriers	Supplier qualification and quality	Scale and brand requirements	Contract manufacturing and compliance

Basic Care can compete effectively where consumers prioritize price and availability. Imodium has greater brand recognition and may retain share during urgent purchases. Pharmacy and grocery private labels can narrow the price gap, increasing pressure on Amazon’s product listing, search visibility, and customer reviews.

Which companies are challenging the market?

Competitive pressure comes from several groups:

• Kenvue, through Imodium-branded products.
• Retail private-label programs operated by pharmacy, grocery, mass-merchandise, and e-commerce retailers.
• Generic drug manufacturers and contract manufacturers.
• International OTC manufacturers with established loperamide and simethicone platforms.
• Combination-product suppliers selling through online marketplaces.

The market is fragmented at the manufacturing level but concentrated at the retail-distribution level. Retailer access, forecast accuracy, fill rates, and product reviews can matter more than patent ownership.

What manufacturing and IP barriers exist?

Manufacturing barriers are manageable but meaningful. They include:

• Reliable sourcing of pharmaceutical-grade loperamide hydrochloride.
• Consistent simethicone quality and dispersion.
• Low-dose blend uniformity.
• Tablet hardness and friability control.
• Rapid disintegration after coating.
• Stability under humidity and temperature stress.
• Packaging compatibility.
• Batch release testing.
• FDA-compliant OTC labeling.
• Supplier-change qualification.

The principal IP barrier is weak. The practical barrier is execution. A manufacturer with validated blending, compression, coating, and packaging processes can enter the market without licensing a foundational patent.

What licensing deals affect the product?

A standard Basic Care product does not require a conventional drug patent license for loperamide or simethicone. Commercial arrangements are more likely to involve:

• Contract manufacturing.
• Private-label supply agreements.
• Active pharmaceutical ingredient supply.
• Packaging and artwork licenses.
• Retail distribution agreements.
• Quality and regulatory services.

The most valuable contract terms are likely to concern capacity reservation, cost adjustment, service levels, recall allocation, audit rights, change control, and exclusivity by channel or geography.

What geographic coverage is available?

The United States is the clearest opportunity because loperamide and simethicone are established OTC actives with mature consumer demand. International expansion requires country-specific review of:

• OTC monograph or marketing-authorization requirements.
• Approved indications.
• Maximum daily doses.
• Pediatric labeling.
• Combination-product rules.
• Local pharmacovigilance obligations.
• Language and packaging requirements.
• Import and serialization rules.

The United Kingdom, European Union, Canada, Australia, and selected Latin American markets may require different regulatory strategies. A U.S. label cannot be assumed to transfer directly to another jurisdiction.

What revenue exposure does the product create?

Revenue exposure depends on unit volume, retailer pricing, package size, promotional intensity, and channel concentration. The product is more likely to generate repeatable but modest revenue per unit than prescription-drug-like margins.

Commercial upside is strongest when the sponsor controls:

• A high-traffic retail channel.
• A differentiated pack size.
• Search placement and online availability.
• A low-cost manufacturing network.
• Multiple related gastrointestinal products.
• Seasonal inventory planning.

The main downside risks are retailer delisting, supply interruptions, product complaints, safety-related publicity, and price compression.

Key Takeaways

• Basic Care Loperamide Hydrochloride and Simethicone is a mature OTC combination with limited patent-based exclusivity.
• The active ingredients are loperamide hydrochloride and simethicone, typically in a 2 mg/125 mg caplet format.
• Excipient strategy should focus on blend uniformity, simethicone dispersion, rapid disintegration, tablet robustness, and moisture control.
• The strongest commercial opportunities are orally disintegrating tablets, chewables, unit-dose travel packs, and low-cost private-label caplets.
• A standard product is unlikely to have a meaningful Orange Book patent estate or Paragraph IV exposure.
• Biosimilar risk is irrelevant because the product contains small-molecule OTC actives.
• Manufacturing qualification, retailer access, packaging, and supply reliability are more important barriers than foundational patents.
• Safety and misuse concerns favor controlled packaging, clear labeling, and disciplined pack-size selection.
• A differentiated formulation may support patents, but narrow claim scope and prior-art risk will limit exclusivity value.
• The product’s commercial value depends primarily on private-label economics, retail distribution, and operational performance.

FAQs

Can a new company launch a loperamide and simethicone product without licensing Basic Care?

Yes. A compliant manufacturer can generally enter the OTC market using the applicable FDA monograph framework, provided the product meets active-ingredient, labeling, manufacturing, and packaging requirements.

Is simethicone an excipient or an active ingredient in this product?

Simethicone is an active ingredient because it is labeled to relieve gas-related symptoms. Its formulation behavior resembles that of a hydrophobic excipient, so dispersion and wetting remain important manufacturing considerations.

Could an orally disintegrating loperamide and simethicone product obtain patent protection?

Potentially. Protection would most likely depend on a specific technical formulation, release profile, taste-masking system, manufacturing process, or stability result rather than on the combination itself.

Does a private-label OTC product need an Orange Book patent listing?

No. A conventional OTC monograph product generally does not depend on an Orange Book-listed patent. The Orange Book becomes more relevant when a product is marketed under an approved application with eligible patent listings.

What is the best commercial differentiation strategy for this combination?

The strongest options are lower price, faster disintegration, better taste, travel-oriented unit dosing, improved packaging, and reliable availability. For a private-label product, retailer placement and supply performance are likely to produce more value than broad formulation patent claims.

References

1. U.S. Food and Drug Administration. (2024). DailyMed: Loperamide hydrochloride and simethicone tablet labeling. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 329: Antidiarrheal products for over-the-counter human use. Electronic Code of Federal Regulations.

3. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 332: Antiflatulent products for over-the-counter human use. Electronic Code of Federal Regulations.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2018). FDA limits packaging for anti-diarrhea medicine loperamide, Imodium A-D, to encourage safe use. U.S. Department of Health and Human Services.